Stroke is the leading cause of disabilities and cognitive deficits, accounting for 5.2% of all
mortalities worldwide. Transient or permanent occlusion of cerebral vessels leads to …

Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Background The value of administering intravenous alteplase before endovascular
treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in …

Background Whether thrombectomy alone is equally as effective as intravenous alteplase
plus thrombectomy remains controversial. We aimed to determine whether thrombectomy …

Background The benefit of combined treatment with intravenous thrombolysis before
endovascular thrombectomy in patients with acute ischaemic stroke caused by large vessel …

The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …

Background Intravenous thrombolysis is recommended before endovascular treatment, but
its value has been questioned in patients who are admitted directly to centres capable of …

Six randomized controlled clinical trials have assessed whether mechanical thrombectomy
(MT) alone is non-inferior to intravenous thrombolysis (IVT) plus MT within 4.5 hours of …

卒中是致残和致死的主要疾病之一, 急性缺血性卒中约占全部卒中的80%.
急性缺血性卒中治疗的关键在于尽早开通阻塞血管, 挽救缺血半暗带. 目前被证实有效的急性缺 …

Six randomized controlled clinical trials have assessed whether mechanical thrombectomy
(MT) alone is non-inferior to intravenous thrombolysis (IVT) plus MT within 4.5 hours of …